Immunovant Inc’s recent filing unveils that its Chief Executive Officer Salzmann Peter unloaded Company’s shares for reported $0.49 million on Feb 22 ’24. In the deal valued at $36.15 per share,13,454 shares were sold. As a result of this transaction, Salzmann Peter now holds 931,231 shares worth roughly $29.07 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Barnett Eva Renee sold 2,930 shares, generating $105,920 in total proceeds. Upon selling the shares at $36.15, the Chief Financial Officer now owns 320,420 shares.
Before that, Macias William L. sold 2,221 shares. Immunovant Inc shares valued at $80,289 were divested by the Chief Medical Officer at a price of $36.15 per share. As a result of the transaction, Macias William L. now holds 330,952 shares, worth roughly $10.33 million.
Goldman initiated its Immunovant Inc [IMVT] rating to a Buy in a research note published on March 13, 2024; the price target was $50. A number of analysts have revised their coverage, including JP Morgan’s analysts, who began to cover the stock in mid February with a ‘”an Overweight”‘ rating. Wolfe Research began covering IMVT with “an Outperform” recommendation on February 15, 2024. Deutsche Bank started covering the stock on December 12, 2023. It rated IMVT as “a Buy”.
Price Performance Review of IMVT
On Monday, Immunovant Inc [NASDAQ:IMVT] saw its stock fall -3.04% to $31.22. Over the last five days, the stock has gained 3.14%. Immunovant Inc shares have fallen nearly -25.90% since the year began. Nevertheless, the stocks have risen 99.87% over the past one year. While a 52-week high of $45.58 was reached on 01/09/24, a 52-week low of $14.05 was recorded on 03/14/24. SMA at 50 days reached $35.88, while 200 days put it at $30.98. A total of 0.89 million shares were traded, compared to the trading of 3.53 million shares in the previous session.
Levels Of Support And Resistance For IMVT Stock
The 24-hour chart illustrates a support level at 30.58, which if violated will result in even more drops to 29.94. On the upside, there is a resistance level at 32.32. A further resistance level may holdings at 33.42. The Relative Strength Index (RSI) on the 14-day chart is 38.14, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.88%. Stochastics %K at 39.30% indicates the stock is a holding.
How much short interest is there in Immunovant Inc?
A steep rise in short interest was recorded in Immunovant Inc stocks on Feb 29, 2024, growing by 0.37 million shares to a total of 8.68 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 8.31 million shares. There was a rise of 4.26%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 12.42% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.62.
